A detailed history of Algert Global LLC transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Algert Global LLC holds 39,687 shares of FULC stock, worth $172,638. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,687
Previous 41,303 3.91%
Holding current value
$172,638
Previous $256,000 44.53%
% of portfolio
0.0%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$3.18 - $9.74 $5,138 - $15,739
-1,616 Reduced 3.91%
39,687 $142,000
Q2 2024

Aug 14, 2024

BUY
$5.98 - $9.31 $165,245 - $257,263
27,633 Added 202.14%
41,303 $256,000
Q1 2024

May 14, 2024

SELL
$6.7 - $12.0 $81,472 - $145,920
-12,160 Reduced 47.08%
13,670 $129,000
Q4 2023

Feb 14, 2024

SELL
$3.18 - $6.86 $16,472 - $35,534
-5,180 Reduced 16.7%
25,830 $174,000
Q3 2023

Nov 13, 2023

BUY
$3.25 - $6.08 $100,782 - $188,540
31,010 New
31,010 $138,000

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $226M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.